Skin rash. Rash and other nonspecific skin eruption
Conditions
Interventions
Intervention 1: Intervention group: Patients with skin rash has been induced by Cetuximab,will use topical 0.1% vitamin K cream, including a combination of vitamin K1 (Phytonadione) produced by Caspia
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with metastatic colorectal cancer that are candidates for treatment with Cetuximab . Patients with grade 1 to 4 skin lesions, after using Cetuximab(based on Common Terminology Criteria for Adverse Events4 (CTCAE4)) Be over 18 years old The patient should not undergo radiotherapy. Have a desire to participate in the study.
Exclusion criteria
Exclusion criteria: The patient has skin lesions before receiving cetuximab (including rash, acne, pustules, inflammatory erythema) Being pregnant or in breastfeeding duration Previous history of allergies to compounds containing vitamin K Has a psychiatric disorder that is not able to participate in the study For other reasons, he is taking drugs that have a drug interaction with topical vitamin K Be taking medicinal compounds containing vitamin K
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grade of skin lesions, based on Common Terminology Criteria for Adverse Events4 (CTCAE4). Timepoint: At the beginning of the study and 4 and 8 weeks after using topical vitamin K. Method of measurement: Based on CTCEA4. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahmoud Rezaei
Esfahan University of Medical Sciences
Outcome results
None listed